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Abstract 
India's pharmaceutical sector is currently undergoing unprecedented change. India ratified the agreement establishing the World 
Trade Organization (WTO). This Agreement, inter-alia, contains an Agreement on Trade Related Aspects of Intellectual Property 
Rights (TRIPS) which lays down minimum standards for protection and enforcement of IPR which are required to promote 
effective and adequate protection of IPR with a view to reducing distortions. Much of this is due to the country's introduction, on 
January 1, 2005, of a system of product patents; before that, only patents for processes were permitted to be issued. The purpose 
of this research paper is to study the problems faced by innover in filling patent in Indian pharmaceutical industry. The paper also 
includes study of problem related to research and development activities, patent filling process etc. 
© 2013 The Authors. Published by Elsevier B.V. 
Selection and/or peer-review under responsibility of Symbiosis Institute of Management Studies. 
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1. Introduction 
The introduction of the product patent law in India from January 01, 2005 has been a fundamental change in the 
Indian pharma industry. The law is expected to put an end to some of the earlier practices followed by Indian 
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companies and prompt them to focus on discovery led research to introduce patented molecules.  India's 
entrepreneurial pharmaceutical manufacturers are now beginning to leverage benefits from the introduction of the 
nation's product patent system on January 1, 2005. Most will be unable to develop the financial muscle necessary to 
embark on R&D for innovative new products, but their scientific, technical and manufacturing skills, developed 
under the country's 25-year process patent system, perfectly match the requirements of global drug manufacturers 
that are increasingly seeking to offshore many research and manufacturing activities previously performed in-house. 
The lack of patent protection made the Indian market undesirable to the multinational companies that had dominated 
the market, and while they streamed out. Indian companies carved a niche in both the Indian and world markets with 
their expertise in reverse-engineering new processes for manufacturing drugs at low costs. Although some of the 
larger companies have taken baby steps towards drug innovation, the industry as a whole has been following this 
business model. Patent amendment should be favored for the patent protection India which will in turn India an ideal 
center for the research and the domestic manufacturers will be benefited but the loopholes in it should be rectified 
for the all round development. 
2. Research Problem and Questions 
This problem (questions) can be split into the following questions: 
a) How companies are captivating amended intellectual property act 2005? 
b) What is various research & development and business strategies have been adopted by Indian pharma 
industry to sustain business after the issuance of patent ordinance in 2005? 
c) Are pharmaceutical companies finding any complicatedness in overall patent filling process? 
3. Importance of the Study 
In order to be evidence for the Indian Pharma companies in a path that have huge benefits by amended Patent act on 
the marketing activity in the way that best fit the consumers. This study will be useful for providing factors that 
mostly affect the Indian pharma companies for patenting the molecule. 
4. Objectives of the Study 
x To study the impact of intellectual property rights through innovation in pharma drug manufacturing 
companies. 
x To focus on the various strategies adopted by Indian pharma industry to sustain business after the issuance 
of patent ordinance in 2005.  
x To study problems Indian pharma companies are facing in overall patent filling process. 
5. Research Limitations 
a) The study was restricted to pharmaceutical industry located around Mumbai and Pune region, lawyers and 
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doctors located in Pune. 
b) The study focused on pharmaceutical industry and Amended patent act 2005 only and hence results of the 
analysis are not applicable to any other type of industry. 
6. Literature Review 
The research article by CBO Study discusses about research and development cost, time and risk. Research and 
development requires huge capital investment at the same time, the risk is high in research and development activity 
in the form of success which means the cost of successes and failures alike. Even time require is long as 11.8 years 
to come up with patented product. According to the pharmaceutical company have various strategy like instead of 
going for mew molecule they modify existing molecule. The strategy depends on company policy of profitability. 
The research article by Hemant N. Joshi discusses on the problem which Indian pharmaceutical companies are 
facing. Research and development activity demands huge capital investment, skilled people, technology etc (around 
$300 million to $ 600 million of investment) where success rate is even very little. Indian pharmaceutical companies 
have skilled people, strong IT back up, technology but is deficient in capital investment. Even Due to Amended 
patent act 2005, which globally harmonized patent system that prohibit the replication or reverse engineering of 
patent protected new drugs, patent holding companies are enjoying monopoly. This is affecting availability & 
affordability of patented drugs to common Indian customers. 
 
The research article by Ravi Kiran, SunitaMistra discuss about the R & D activity and patenting activity of Indian 
pharmaceutical companies post TRIPS period. The study by Gupta (2000) highlights that after the establishment of 
WTO; there is a greater effort by the Indian R&D organizations to obtain patents in USA. Kubo (2004) opines that 
R&D intensity and patent to R&D ratio has increased in India after 1995 for large pharmaceutical firms. Grace 
(2004) is of the opinion that most successful firms investing an increasing amount in R&D including in partnership 
with MNCs, & with increasingly positive results. Dhar & Gopakumar (2006) also accept that there has been an 
increase in the R&D spending of some of the leading firms, in particular, Ranbaxy and Dr Reddy’s. As a result, 
R&D intensities of the firms have improved. The article by Richard E. Rowberg talks about the cost allocation of 
the R & D department. As discussed above the research and development department demands huge capital 
investment. Cost allocation plays very important role in research and development activity which depends on 
company strategy. India’s leading drug manufacturers are becoming global players, utilizing both organic growth, 
through the gradual development of their business, and mergers and acquisitions(M&A) as they seek to boost their 
presence in existing markets and open up new ones. However, there are significant obstacles ahead, & overcoming 
them will require new commitment by both industry & government, & unprecedented levels of partnership between 
them.  
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7. Research methodology 
Research design: Descriptive research design. 
Population: Indian pharmaceutical companies, lawyers and doctors 
Sampling Area: Mumbai and Pune region 
The term Mumbai and Pune Region used in this study refers to area carved out by the pharmaceutical industry for its 
high rate of development. Mumbai and Pune region as understood in the Pharmaceutical Marketing phraseology is 
quite a large area spread over. There are around 300 pharmaceutical companies which are catering to the population 
of this area. Hence it was possible only to obtain data from the representatively selected top 25 pharmaceutical 
companies based on purposive sampling, in Mumbai and Pune region, having major market share. Doctors with 
different specialization like radiologist, gynecologist, cardiologist etc and practicing since 8 years are considered 
from Pune city. Patent experts practicing in private firms are contacted to collect information, whose experience is 
more than 10 years in Pune city. 
Sampling Technique: Non-probability purposive sampling for pharmaceutical companies, stratified convenience 
sampling for lawyers and doctors 
Sample Size:  Total -60 
Doctors – 30 with different specializations 
Patent Experts – 5 practicing in private firms 
R and D, Legal department etc of Indian pharmaceutical company – 25 
Research Instrument: Personal Interview, structured Questionnaire 
Tool: With a view to obtain data from the field, three different questionnaires designed , one for the pharma 
companies managers, second for patent experts  & the other for doctors, have been prepared & administered. The 
responses received have been tabulated & statistically analyzed. 
 
E sources:  Internet, sites, journals, publications, articles, online research papers etc. 
Data Analysis procedure The field survey and personal interview technique adopted for data collection and collected 
data has been tabulated and presented with the help of graphs, tables and charts. Both descriptive and inferential 
statistics were used in presenting and analyzing the data. Descriptive tools such as frequency counts, mean scores, 
percentages were calculated for the statements on the questionnaire in order to determine the impact and its related 
issues. 
8. Data analysis 
a) What are the different strategies you are using for research and development department?   
 
i. Own department is working actively       
ii. Collaboration withpharma company, government, NGO, WHO , Educational institutes 
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iii. Outsourcing 
iv. Risk sharing partnership 
v. Agreement with foreign companies. 
vi. Hived off of R and D activity into different entities. 
vii. merger of R and D units 
viii. Attract investment 
ix. Any other suggestion 
 
Outcome: 5% own department working actively, 18 % collaboration with the other companies, 9 % outsourcing, 8% 
agreement with foreign companies, 12 % risk sharing partnership, 10 % hived off research and development 
activity, 10 % merger of R & D units, 8 % attracting investment. 
Interpretation- The different strategies of Indian pharmaceutical company are using for research and development 
department. 
 
b) Indian intellectual property right system is user friendly. 
 
 
Outcome- 80 % of the total says that IPR system is user friendly. Still there are some loopholes in it. 
 
 
 
 
 
 
 
 
 
 
 
80%
20%
Yes
No
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c) Process of filling patent is user friendly. 
Yes                                  No 
 
 
 
 
Outcome- 60 % of the total says that process is fine. 
d) Period required to register to patent is more than required. 
Yes                                  No 
 
 
 
Outcome- 40 % of the total says that period required to register is more than required. 
Interpretation- IPR system is useful due to its user friendliness. The reduction in Period required to register patent 
will be of great use.The lengthy time period between patent filing and placing a product on the market means that 
pharmaceutical manufacturers receive far shorter periods of patent exclusivity than is the case for other patent 
dependent industries. 
 
5. Problems faced by pharmaceutical companies while registering IPR. 
a. Documentation 
b. Financial support for innovation 
c. Technology 
d. Unavailability of R and D center 
 
 
60%
40% Yes
No
40%
60%
Yes
No
835 Sarika Zambad and B.R. Londhe /  Procedia Economics and Finance  11 ( 2014 )  829 – 837 
 
Outcome- 36 % documentation, 27% financial support,27% technology, 10% unavailability of R and D are 
problems while registering IPR. 
Interpretation-Documentation, Financial Support & Technology these are the major problem areas faced by 
pharmaceutical companies while registering IPR. 
 
6. Rank the following problem in ascending order in inventing patented molecule drug 
 
a) Research and Development facility 
b) More time require for innovation 
c) Huge capital investment 
d) Lack of Human resource 
e) Insufficient venture capital funding 
f) Paucity of trained person 
g) different  private equity market 
h) Early stage funding. 
i) Any other 
 
Outcome- 22% R & D facility,19%  more time require for innovation,18%  huge capital investments, 6%  lack of 
human resources, 8% insufficient venture capital funding, 5% paucity of trained person, 9% different equity market, 
13% early stage funding. 
Interpretation -Research and Development facility, more time require for innovation, huge capital investments are 
the top 3 Problems in inventing patented molecule. 
 
9. Finding and conclusion 
a) According to the research study for R and D and business strategies, pharmaceutical industry is adopting 
various strategies depending on company’s policy.  The implication which comes out is that the present 
situation is challenging, but at the same time it throws up several new opportunities for Indian pharma 
companies. What worked in the past may not necessarily hold them in good path in the future. Companies 
which take advantage of the fundamental changes, that industry go through and re-jig their strategies 
accordingly will be able to successfully steer the future in Indian pharmaceutical company.  
b) The finding which comes out from the study is that Indian intellectual property right system is user friendly 
to Indian pharmaceutical company.  
c) The finding which comes out from the research is that process of filling patent to some extend is user 
friendly to Indian pharmaceutical company.  
d) The lengthy time period between patent filing and placing a product on the market means that 
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pharmaceutical manufacturers receive far shorter periods of patent exclusivity than is the case for other 
patent dependent industries. The inference which comes out from the analysis is that period required to 
register patent is averagely more than required time.  
e) The filing of a patent application is the first step in securing a patent. If the application is submitted with 
the Patent Office, the officer then starts publication and examining the authenticity of invention. If 
everything is in order, the patent would be granted to the inventor. According to the research study about 
problems faced by pharmaceutical companies while registering IPR commonly is Documentation work, 
financial support, Technology, Unavailability of R & D center. The implication which comes out from the 
analysis is that documentation, financial Support & technology these are the major problem areas 
respectively faced by pharmaceutical companies while registering IPR. 
f) The inference that comes out is R & D facility, more time requires for innovation and huge capital 
investment are the top 3 major problems to Indian Pharma Company in inventing patented molecule. 
10. Suggestions  
a) Indian Pharmaceutical sector looks extremely positive. They can adopt various strategies to increase R & D 
activity as, Contract Research and Manufacturing Services (CRAMS), Contract Clinical Trials, Global alliances 
& M&A's, Industry academic collaboration, improving the Quality of Public Research etc looking at the 
resources. 
b) Giving India the IPR edge: Problems faced by Indian pharmaceutical companies while registering IPR 
commonly are documentation work, financial support, Technology, unavailability of R & D center while 
registering IPR. Following are the suggestions as, 
c) There is a need to expedite for the process of examining the patent application to stimulate innovation. b. A 
time limit for filing & disposing of pre-grant oppositions should be provided at the earliest. 
d) Pharmaceutical must improve its R&D productivity and its legal framework must be altered to promote 
innovation and discourage imitation and prove that its products really work and provide value for money.  
e) Provide financial incentives to encourage innovations & research. 
f) Different institutions should be funded for undergoing research. The Indian education system and the 
industry need to come together to plug the shortage, which will require significant investment. 
 
Possible options for IPI 
As far as India’s pharmaceutical industry is concerned, various options are possible in the WTO regime. 
These are to: 
(a) Manufacture off patented generic drugs, 
(b) Produce patented drugs under compulsory licensing or cross licensing, 
(c) Invest in R&D to engage in new product development, 
(d) Produce patented and other drugs on contract basis, 
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(e) Explore the possibilities of new drug delivery mechanisms and alternative use of existing drugs, and 
(f) Collaborate with multinationals to engage in R&D, clinical trials, product development or marketing the 
patented product on a contract basis and so on. 
 
Besides these strategies, India’s strength lays in process development skills. This expertise utilized within the WTO 
framework with emphasis on quality standards will provide India a competitive advantage over other Asian 
countries. 
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